A Multi-Center, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rilonacept Administered Subcutaneously for the Treatment of an Acute Gout Flare.

Trial Profile

A Multi-Center, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rilonacept Administered Subcutaneously for the Treatment of an Acute Gout Flare.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2017

At a glance

  • Drugs Rilonacept (Primary) ; Indometacin
  • Indications Gout
  • Focus Registrational; Therapeutic Use
  • Acronyms SURGE
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 09 Jun 2010 Primary endpoint 'Patient assessment of pain' has not been met, according to a Regeneron Pharmaceuticals media release.
    • 26 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Feb 2010 Status changed from recruiting to active, no longer recruiting, as reported by Regeneron Pharmaceuticals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top